LogoLogo
LogoLogo

måndag 26 okt.mån 26 okt.

Kontakta oss

redaktionen@placera.se

Frågor om forumet

support@placera.se

Tjänster

  • Redeye
  • SME Direkt
  • Investtech

Annonsera

  • Marc Lindh

    annons@placera.se

    073 855 81 42

Ansvarig utgivare

Peter Benson

Mer

  • Om Placera
  • Till Avanza
  • RSS
  • Personuppgifter
  • Användarvillkor
LogoLogo

Box 1399, 111 93 Stockholm

OMX Stockholm 30

0,41%

(vid stängning)

Idag, 04:44

Newborn Town Partners with Viggle to Launch AI-Native Game: Enhancing Social Gaming Experiences with Next-Generation Physics-Native World Model
Utz Brands A

Idag, 04:00

MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD

Idag, 03:05

Tin Men Capital leads US$7.4M Series A for Vision AI startup Ailytics to expand across APAC, US and Gulf

Idag, 02:30

Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

Idag, 02:10

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

Idag, 02:00

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

Idag, 02:00

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
Dick's Sporting Goods

Idag, 01:49

DKS Deadline: DKS Investors Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit

Idag, 01:04

Martial Arts Legend and Former UFC Referee Cecil Peoples Releases Autobiography
York Space Systems

Idag, 01:01

YSS Deadline: YSS Investors Have Opportunity to Lead York Space Systems Inc. Securities Lawsuit

Idag, 00:59

Martial Arts History Museum, A Cultural Gem in Glendale
Gildan Activewear

Idag, 00:22

GIL Investors Have Opportunity to Lead Gildan Activewear Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Kaldvik

Igår, 23:57

KALDVÍK AS (KLDVK): Extension of waiver period
AstraZeneca

Igår, 17:41

Sonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
AstraZeneca

Igår, 17:37

Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso

Igår, 17:31

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Hims & Hers Health

Igår, 17:24

INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
Gildan Activewear

Igår, 16:45

INVESTOR DEADLINE: Gildan Activewear Inc. Investors with Substantial Losses May Seek to Lead the Gildan Activewear Class Action Lawsuit Before December 14, 2026 Deadline - GIL
Johnson & Johnson

Igår, 15:45

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Igår, 14:38

BAC Investors Have Opportunity to Lead Bank of America Corporation Securities Fraud Lawsuit

Igår, 13:01

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Genmab ADR

Igår, 13:00

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Igår, 12:37

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Borr Drilling

Igår, 12:22

Borr Drilling Limited - Prospector 5 Rig Incident
Eli Lilly

Igår, 09:30

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Johnson & Johnson

Igår, 09:30

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
BW Energy Limited

Igår, 08:24

BW Energy: Drilling rig incident on the Dussafu licence
Borr Drilling

Igår, 08:08

Borr Drilling Limited – Prospector 5 Rig Incident

Igår, 08:01

Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026

Igår, 08:00

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

Igår, 08:00

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Flotek Industries

Igår, 03:01

Flotek Deadline: FTK Investors Have Opportunity to Lead Flotek Industries, Inc. Securities Fraud Lawsuit
Hyliion A

Igår, 02:21

HYLN Deadline: HYLN Investors Have Opportunity to Lead Hyliion Holdings Corp. Securities Fraud Lawsuit

Igår, 01:44

HomeToGo SE: Unauthorized data exfiltration at subsidiary SECRA Bookings GmbH
Yiren Digital ADR

24 oktober, 21:35

Rosen Law Firm Encourages Yiren Digital Ltd. Investors to Inquire About Securities Class Action Investigation - YRD
AstraZeneca

24 oktober, 18:37

Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
AstraZeneca

24 oktober, 18:31

Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
AMGEN Inc.

24 oktober, 18:30

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Darden Restaurants

24 oktober, 17:01

Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Darden Restaurants, Inc. for Alleged Failure to Reimburse Employees' Business Expenses
Johnson & Johnson

24 oktober, 16:54

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

24 oktober, 16:15

Winners of the 2026 INPD Awards Announced, C-Beauty Takes Home Multiple Prestigious Honors
Genmab ADR

24 oktober, 15:00

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

24 oktober, 15:00

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Alkane Resources Ltd

24 oktober, 12:39

Alkanes borrningar bekräftar och utvidgar guld-antimon-mineralsystemet vid Nagambie i Victoria
BioInvent

24 oktober, 11:00

BioInvent's BI-1808 and KEYTRUDA® Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
BioInvent

24 oktober, 11:00

BioInvents BI-1808 och KEYTRUDA® ger varaktiga responser hos kraftigt förbehandlade patienter med platinaresistent äggstockscancer
Orion Oyj B

24 oktober, 10:35

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks

24 oktober, 10:30

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Eli Lilly

24 oktober, 10:30

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

24 oktober, 08:30

AI and EV Boom Draws $690 Million in Advanced Materials Investment Plans to Thailand